Nektar quickly drops opioid drug after FDA panel rejection

Nektar quickly drops opioid drug after FDA panel rejection

Publication date: Jan 16, 2020

The FDA panel’s decision is “disappointing for patients suffering from chronic pain and the physicians that treat those patients who are currently relying on existing opioid therapies,” Nektar said in a Jan. 14 statement.

In briefing documents and a series of questions for the panel members, the FDA highlighted that the company had only conducted one pivotal efficacy study to support the drug’s review.

Because the company no longer needs to spend money on commercialization and post-approval studies for oxycodegol, Nektar said it expects cost savings of $75 million to $125 million this year.

Concepts Keywords
Anesthesia Main focus cancer
Bristol Myers Opioid use disorder
Bristol Myers Squibb Health
Cancer RTT
Chronic Pain Bempegaldesleukin
FDA Banjalučka Pivara
Nektar Psychoactive drugs
Opioid Chronic pain physicians
Opioid Addiction


Type Source Name
disease MESH cancer
drug DRUGBANK Tropicamide
disease MESH chronic pain
disease MESH suffering
disease MESH opioid addiction


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *